anti fluorescence quenching mounting solution (Beyotime)
Beyotime is a verified supplier 
Beyotime manufactures this product 
99
Structured Review
Beyotime
anti fluorescence quenching mounting solution
Anti Fluorescence Quenching Mounting Solution, supplied by Beyotime, used in various techniques. Bioz Stars score: 99/100, based on 32109 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mounting+solution+containing+dapi+p0131/DAPI/pm39476572-144-45-51
Average 99 stars, based on 32109 article reviews
Anti Fluorescence Quenching Mounting Solution, supplied by Beyotime, used in various techniques. Bioz Stars score: 99/100, based on 32109 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mounting+solution+containing+dapi+p0131/DAPI/pm39476572-144-45-51
Average 99 stars, based on 32109 article reviews
anti fluorescence quenching mounting solution - by Bioz Stars,
2026-09
99/100 stars
Images
Related Articles
Incubation:Article Title: Self-healing hydrogel reduces inflammation through ANT1/OPTN axis mediated mitophagy for spinal cord injury repair Article Snippet: Cells were blocked with 1 % BSA for 30 min and incubated with anti-NLRP3 (1:200, Gb114320, Rabbit, Servicebio, China), and anti-ANT1(1:200, A15027, Rabbit, ABclonal, Wuhan, China) overnight at 4 ◦C. .. Then, the samples were rinsed with PBST for 3 times and followed incubated with CoraLite488-conjugated Goat Anti-Rabbit IgG(H + L) (1:250, SA00013-2, Goat, Proteintech, Chicago, USA) and CoraLite594-conjugated Goat Anti-Rabbit IgG(H + L) (1:250, SA000134, Goat, Proteintech) secondary antibodies for 2 h. After that, the samples were rinsed with PBST for 3 times and stained nuclei with mounting solution containing Article Title: Enhancing therapeutic efficacy in homologous recombination-proficient pancreatic cancer via the combination of PARP1-PROTAC and a BRD4 inhibitor. Article Snippet: Currently, poly (ADP-ribose) polymerase inhibitors (PARPi) have been approved by U.S. Food and Drug Administration for BRCA-mutated pancreatic cancer therapy.. However, limited indications hinder their further application.. Repression of bromodomain-containing protein 4 (BRD4) can block the homologous recombination (HR) repair pathway and has the potential to enhance the response to PARPi in HR-proficient pancreatic cancer therapy. Article Title: Mitochondrial Calcium Nanoregulators Reverse the Macrophage Proinflammatory Phenotype Through Restoring Mitochondrial Calcium Homeostasis for the Treatment of Osteoarthritis Article Snippet: Incubated with Anti-F4/80 primary antibody (ab6640, Abcam, UK; 1:200) for 12 h at 4°C. .. Then, sections were washed and incubated with Alexa Flour 488 Goat Anti-Mouse IgG (Yeasen, Shanghai, China; 1:200) for 1.5 h at room temperature in the dark, washed and sealed with Article Title: Mitochondrial Calcium Nanoregulators Reverse the Macrophage Proinflammatory Phenotype Through Restoring Mitochondrial Calcium Homeostasis for the Treatment of Osteoarthritis Article Snippet: Incubated with Anti-F4/80 primary antibody (ab6640, Abcam, UK; 1:200) for 12 h at 4°C. .. Then, sections were washed and incubated with Alexa Flour 488 Goat Anti-Mouse IgG (Yeasen, Shanghai, China; 1:200) for 1.5 h at room temperature in the dark, washed and sealed with Staining:Article Title: Self-healing hydrogel reduces inflammation through ANT1/OPTN axis mediated mitophagy for spinal cord injury repair Article Snippet: Cells were blocked with 1 % BSA for 30 min and incubated with anti-NLRP3 (1:200, Gb114320, Rabbit, Servicebio, China), and anti-ANT1(1:200, A15027, Rabbit, ABclonal, Wuhan, China) overnight at 4 ◦C. .. Then, the samples were rinsed with PBST for 3 times and followed incubated with CoraLite488-conjugated Goat Anti-Rabbit IgG(H + L) (1:250, SA00013-2, Goat, Proteintech, Chicago, USA) and CoraLite594-conjugated Goat Anti-Rabbit IgG(H + L) (1:250, SA000134, Goat, Proteintech) secondary antibodies for 2 h. After that, the samples were rinsed with PBST for 3 times and stained nuclei with mounting solution containing Article Title: Enhancing therapeutic efficacy in homologous recombination-proficient pancreatic cancer via the combination of PARP1-PROTAC and a BRD4 inhibitor. Article Snippet: Currently, poly (ADP-ribose) polymerase inhibitors (PARPi) have been approved by U.S. Food and Drug Administration for BRCA-mutated pancreatic cancer therapy.. However, limited indications hinder their further application.. Repression of bromodomain-containing protein 4 (BRD4) can block the homologous recombination (HR) repair pathway and has the potential to enhance the response to PARPi in HR-proficient pancreatic cancer therapy. |